ArticleCureus2024
Assessing a Novel Thyroid-Stimulating Antibody Bioassay as a Predictor of Radioactive Iodine Therapy Efficacy in Graves' Disease.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNo studies have reported the use of the Biosensor TSAb assay (TSAb (Bio)) for predicting the therapeutic efficacy of radioactive iodine therapy (RAIT) for Graves' disease (GD). Therefore, we evaluated the usefulness of this novel thyroid-stimulating antibody (TSAb) bioassay kit, which uses a cyclic adenosine monophosphate (cAMP) biosensor, in predicting the therapeutic efficacy of RAIT in 20 patients with GD.
methodsWe defined the RAIT outcome using two criteria: (i) thyroid weight reduction to <8 g and (ii) thyroid weight reduction to >80% at 12 months post-RAIT. For criteria (i) and (ii), regression analysis was performed for thyroid-stimulating hormone (TSH) receptor autoantibody (TRAb), TSAb (Bio), TSAb (Bio)/TRAb, I-131 absorbed dose/TSAb (Bio), and I-131 absorbed dose/(TSAb (Bio)/TRAb). After evaluating the significance of each factor, receiver operating characteristic (ROC) analysis was also performed.
resultsAmong the five aforementioned anti-TSH receptor antibody parameters, only I-131 absorbed dose/(TSAb (Bio)/TRAb) showed statistical significance in the multivariate analysis (p = 0.004 and p = 0.021 for each criterion). Although I-131 absorbed dose/(TSAb (Bio)/TRAb) correlated significantly with the thyroid weight (r = -0.54, p = 0.015), it did not correlate with thyroid weight reduction rates at 12 months post-RAIT. ROC analysis also demonstrated a good predictive value (area under the curve of approximately 0.8 with a cut-off value of 3.9) for I-131 absorbed dose/(TSAb (Bio)/TRAb) in predicting thyroid weight at 12 months post-RAIT.
conclusionsTSAb (Bio) is a useful predictor of RAIT efficacy when evaluated as I-131 absorbed dose/(TSAb (Bio)/TRAb). This index was defined by dividing a factor that positively affects RAIT outcomes (I-131 absorbed dose) by a factor negatively affecting it (i.e., (TSAb (Bio)/TRAb)). The therapeutic efficacy of RAIT can be expected with an I-131 absorbed dose/(TSAb (Bio)/TRAb) value of ≥3.9. Adjusting the I-131 dosage based on this index may lead to more effective treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.